ANAB ▲ +5.7% - AnaptysBio, Inc. $ANAB - Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer 19-OCT-2026 02:18 PM ET